Biotest AG (HAM:BIO) Cyclically Adjusted Revenue per Share: €14.73 (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BIO Biotest AG HAM:BIO
56 GF Score
Price €40.00
View Full Analysis

What is Biotest AG Cyclically Adjusted Revenue per Share?

Biotest AG HAM:BIO +2.04% 56 Cyclically Adjusted Revenue per Share is €14.73 as of Mar. 2025. GuruFocus rates HAM:BIO with a GF Score™ of 56/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biotest AG's adjusted revenue per share for the three months ended in Mar. 2025 was €3.192. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €14.73 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-08), Biotest AG's current stock price is €40.00. Biotest AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €14.73. Biotest AG's Cyclically Adjusted PS Ratio of today is 2.72.


Biotest AG  (HAM:BIO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biotest AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=40.00/14.73
=2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biotest AG Cyclically Adjusted Revenue per Share Related Terms


Biotest AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biotest AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG Cyclically Adjusted Revenue per Share Chart

Biotest AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.38 12.99 13.86 14.43 14.80

Biotest AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.72 14.76 14.74 14.80 14.73

HAM:BIO vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Biotest AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biotest AG's Cyclically Adjusted PS Ratio falls into.


HAM:BIO
56GF Score
Biotest AG HAM:BIO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotest AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biotest AG's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.192/127.7792*127.7792
=3.192

Current CPI (Mar. 2025) = 127.7792.

Biotest AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 3.630 100.417 4.619
201509 3.293 100.417 4.190
201512 2.949 99.717 3.779
201603 3.711 100.017 4.741
201606 3.417 100.717 4.335
201609 3.333 101.017 4.216
201612 -0.147 101.217 -0.186
201703 1.669 101.417 2.103
201706 2.373 102.117 2.969
201709 2.536 102.717 3.155
201712 2.777 102.617 3.458
201803 2.184 102.917 2.712
201806 2.848 104.017 3.499
201809 2.266 104.718 2.765
201812 2.798 104.217 3.431
201903 2.583 104.217 3.167
201906 2.573 105.718 3.110
201909 2.648 106.018 3.192
201912 2.507 105.818 3.027
202003 2.533 105.718 3.062
202006 3.782 106.618 4.533
202009 2.758 105.818 3.330
202012 3.520 105.518 4.263
202103 3.149 107.518 3.742
202106 3.697 108.486 4.354
202109 2.924 109.435 3.414
202112 3.435 110.384 3.976
202203 3.075 113.968 3.448
202206 3.567 115.760 3.937
202209 2.787 118.818 2.997
202212 3.848 119.345 4.120
202303 3.045 122.402 3.179
202306 3.914 123.140 4.061
202309 5.664 124.195 5.827
202312 4.657 123.773 4.808
202403 5.398 125.038 5.516
202406 3.880 125.882 3.938
202409 4.051 126.198 4.102
202412 5.143 127.041 5.173
202503 3.192 127.779 3.192

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €14.73 mean?
Biotest AG (HAM:BIO) has a Cyclically Adjusted Revenue per Share of €14.73 as of Mar. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotest AG and its competitors.
Is Biotest AG's Cyclically Adjusted Revenue per Share too high?
Biotest AG's current Cyclically Adjusted Revenue per Share is €14.73. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Biotest AG's Cyclically Adjusted Revenue per Share of €14.73 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotest AG and its competitors. Biotest AG's current Cyclically Adjusted Revenue per Share is €14.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current Cyclically Adjusted Revenue per Share of €14.73. The current Cyclically Adjusted Revenue per Share is €14.73. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current Cyclically Adjusted Revenue per Share is €14.73 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest AG Business Description

Address Landsteinerstrasse 5, PO Box 10 20 40, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score

Get the complete analysis for HAM:BIO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.00
Price